Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · IEX Real-Time Price · USD
1.450
+0.020 (1.40%)
Apr 26, 2024, 10:33 AM EDT - Market open
Spero Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Spero Therapeutics stock has a target of 7.00, which predicts an increase of 382.76% from the current stock price of 1.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2024.
Analyst Ratings
The average analyst rating for SPRO stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +382.76% | Mar 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +382.76% | Nov 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +382.76% | Sep 5, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7 | Strong Buy | Maintains | $6 → $7 | +382.76% | Aug 14, 2023 |
Financial Forecast
Revenue This Year
49.20M
from 103.78M
Decreased by -52.59%
Revenue Next Year
48.79M
from 49.20M
Decreased by -0.83%
EPS This Year
-0.96
from 0.43
EPS Next Year
-0.97
from -0.96
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 51.7M | 50.4M | 90.5M | 114.0M | 322.9M |
| Avg | 49.2M | 48.8M | 57.4M | 51.9M | 182.5M |
| Low | 46.6M | 46.6M | 25.8M | 12.7M | 75.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -50.2% | 2.4% | 85.5% | 98.7% | 522.7% |
| Avg | -52.6% | -0.8% | 17.6% | -9.6% | 251.9% |
| Low | -55.1% | -5.4% | -47.2% | -77.8% | 45.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.95 | -0.95 | -0.12 | 0.63 | 1.11 |
| Avg | -0.96 | -0.97 | -0.64 | -0.21 | 1.08 |
| Low | -0.97 | -1.04 | -1.13 | -0.99 | 1.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.